An Exploration of Key Issues in IBD: A CME/CE-Certified Microlearning Series

Download All
Learn about late-phase trial results for emerging oral IBD therapies
Millie D. Long, MD, MPH

Updates on Emerging Oral Therapies for IBD

Expert review of safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.

Millie D. Long, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: August 24, 2021 Expired: August 23, 2022

Review safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.

Millie D. Long, MD, MPH Released: August 24, 2021

Clinical trials provide great opportunities for individual patients and the IBD community as a whole, but several barriers prevent optimal recruitment.

Millie D. Long, MD, MPH Released: August 17, 2021
Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue